drug_type
RELEVANT_DRUG
intervention_type
Biological drug (bispecific monoclonal antibody; T‑cell engager)
drug_description
Intravenous bispecific T‑cell–engaging monoclonal antibody that binds BCMA on plasma cells and CD3 on T cells to redirect T‑cell cytotoxicity against BCMA‑positive cells; evaluated to prevent progression of high‑risk smoldering multiple myeloma.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibodies, Bispecific
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
Bispecific monoclonal antibody that binds BCMA on plasma cells and CD3 on T cells, forming an immune synapse to activate TCR/CD3 signaling and redirect T‑cell cytotoxicity (perforin/granzyme) against BCMA‑positive cells, depleting malignant and normal BCMA+ plasma cells.
drug_name
Linvoseltamab (REGN5458)
nct_id_drug_ref
NCT05955508